Sio Gene Therapies, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sio Gene Therapies, Inc.
Avrobio is facing up to the reality of investor skepticism about gene therapy platforms and business models – but can it find a buyer or merger partner to start again?
AstraZeneca has paid $85m upfront to develop Tregs against two autoimmune conditions, type 1 diabetes and inflammatory bowel disease
The proceeds from the series A will be used to progress Dualyx’s preclinical program DT-001 which targets "the highly attractive TNF receptor 2 (TNFR2), widely regarded as a master control switch in immune modulation."
Aesther Healthcare Acquisition extended the deadline to merge with Ocean Biomedical, while Intrinsic Medicine no longer plans to go public by merging with a SPAC. In restructuring news, Otonomy begins liquidation, Celyad cuts last clinical program with cash running out and Clovis files for bankruptcy.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Arvelle Therapeutics GmbH
- Axovant Sciences GmbH
- Axovant Sciences, Inc.
- Axovant Sciences Ltd.
- Roivant Neurosciences Ltd.
- Axovant Gene Therapies Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.